Shareholder value creators in the S&P 500: Year 2003 [PDF]
During 2003, 87% of the companies in the S&P 500 created value, compared to just 17% in 2002. The market value of the 500 companies in 2003 was $10.1 trillion, compared to $7.9 trillion in 2002.
Fernandez, Pablo, Reinoso, Laura
core
Shareholder value creation in Europe. Eurostoxx 50: 1997-2003 [PDF]
2003 was a good year for the shareholders of the companies in the Euro Stoxx 50: the shareholder value creation of these 50 companies was €150,016 million.
Villanueva, Alvaro, Fernandez, Pablo
core
Shareholder Access to Manager-Biased Courts and the Monitoring/Litigation Tradeoff [PDF]
Adequate access to courts by minority shareholders is commonly viewed as an important element of a good corporate governance system. Should shareholders be provided with easy access to courts when judges are unlikely to punish opportunistic managers?
Sergey Stepanov
core
Negotiated shareholder value: The German version of an Anglo-American practice [PDF]
In comparative political economy it has become commonplace to distinguish between two types of corporate governance systems. In shareholder systems, influence over company management is concentrated with institutional investors holding small percentages ...
Vitols, Sigurt
core
The Dark Side of Shareholder Protection: Cross-country Evidence from Innovation Performance [PDF]
Proponents of minority shareholder protection state that national legal institutions protecting small investors boost stock markets and, in turn, long-term countries’ performance. In this paper, we empirically challenge this argument.
Filippo Belloc
core
One-stage assay factor VIII activity reflects AAV-derived factor VIII-enhanced thrombin activation and predicts phenotype. [PDF]
BloodSternberg AR +5 more
europepmc +1 more source
An Ion-Releasing Bioactive Glass Accelerates Skeletal Muscle Regeneration and Functional Recovery Following Acute Injury. [PDF]
J Funct BiomaterKendra JA +5 more
europepmc +1 more source
Data-Driven Fatigue Trajectories in Multiple Sclerosis and Their Predictors. [PDF]
Neurol Neuroimmunol NeuroinflammCruciani A +19 more
europepmc +1 more source
Effect of Cyclosporine Ophthalmic Solution 0.09% on Signs and Symptoms of Dry Eye Disease in Patients Inadequately Controlled on Cyclosporine Ophthalmic Emulsion 0.05%: Results from a Single-Arm, Open-Label, Phase 4 Study. [PDF]
Clin OphthalmolJohnston J +10 more
europepmc +1 more source
Serum proteomic changes in atopic dermatitis patients treated with cyclosporine. [PDF]
PLoS OneOlydam JI +6 more
europepmc +1 more source